Comment on ProQR rises after IPO prices at top of range

ProQR rises after IPO prices at top of range

The company said Thursday it expects $88.4 million in proceeds after expenses and underwriting discounts. ProQR Therapeutics NV says it will use the funds from its IPO for clinical development of its lead product candidate, a therapy intended to treat cystic fibrosis, and for preclinical testing of a second drug.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News